177Lu-FAPI-2286治疗转移性结肠癌末线尝试的经验
本文报告一例49岁高分化结肠腺癌伴肝肺转移患者,在接受化疗、肝移植等多项治疗后,以177Lu-FAPI-2286放射性配体治疗作为最后手段;治疗后癌胚抗原(CEA)持续升高,生化反应不佳,患者于治疗后10周因呼吸功能失代偿死亡。作者认为该案例提示FAP靶向放射性配体治疗在晚期结肠癌中的潜力,并建议更早干预可能有益。
要点
- 转移性结肠癌末线使用177Lu-FAPI-2286后CEA仍持续升高,生化反应不佳。
- 患者于治疗后10周因呼吸功能失代偿死亡。
- 作者提出FAP靶向治疗或宜更早介入,但仅为个案提示。
核心结论
- 177Lu-FAPI-2286作为转移性结肠癌最后手段未能获得生化反应,CEA持续升高。
- 作者认为该案例提示FAP靶向放射性配体治疗在晚期结肠癌中有潜力,更早干预可能有益。
研究设计与样本
- 单例病例报告:49岁男性高分化结肠腺癌伴肝转移,曾接受化疗、腹腔镜结肠造口和射频消融。
- 肝移植后无病生存1年,后CEA升高并发现肝肺新转移,以177Lu-FAPI-2286作为最后手段治疗。
主要发现
- 治疗后生化反应不理想,CEA水平继续上升。
- 患者于治疗10周后出现呼吸功能失代偿并死亡。
临床怎么用
- 个案经验提示FAP靶向放射性配体治疗在晚期结肠癌中值得探索,但需在更早阶段评估可能获益。
局限性
- 仅为单例病例报告,无法确立疗效或安全性结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 49-year-old man diagnosed with well-differentiated adenocarcinoma of the colon, along with liver metastases, underwent several treatments, including chemotherapy, laparoscopic colostomy, and radiofrequency ablation. After receiving a liver transplant, he achieved 1-year disease-free status. However, rising serum levels of carcinoembryonic antigen (CEA) led to further evaluation, which revealed new metastases in the liver and lungs. As a last resort, he was treated with 177 Lu-FAPI-2286 radioligand therapy, but the biochemical response was disappointing, as CEA levels continued to rise. Tragically, the patient experienced respiratory decompensation and passed away 10 weeks after the treatment. This case underscores the potential of FAP-targeted radioligand therapy in managing advanced colon cancer and suggests that earlier intervention might be beneficial.
引用
- Saber Tanha A, Raeisi N, Sadeghi R, et al. Experience With 177 Lu-FAPI-2286 Therapy as the Last Resort in a Patient With Metastatic Colon Cancer. Clin Nucl Med. 2026. PMID: 41941243. doi:10.1097/RLU.0000000000006230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。